ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1033

Comparison of Oral Administration of Diacerein, Intra-Articular Injection of Diacerein Solution, and Intra-Articular Injection of Diacerein-Loaded Nanoparticle in Osteoarthritis Rat Model

Jae Hyun Jung1,2, Sung Jae Choi1,3, Gwan Gyu Song1,2, Sung Eun Kim4 and Hak-Jun Kim5,6, 1Internal Medicine, Korea University College of Medicine, Seoul, Korea, Republic of (South), 2Internal Medicine, Korea University Guro Hospital, Seoul, Korea, Republic of (South), 3Internal Medicine, Korea University Ansan Hospital, Ansan, Korea, Republic of (South), 4Orthopedic Surgery, Korea University Guro Hospitial, Seoul, Korea, Republic of (South), 5Orthopedic Surgery, Korea Univertisy College of Medicine, Seoul, Korea, Republic of (South), 6Orthopedic Surgery, Korea University Guro Hospital, Seoul, Korea, Republic of (South)

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Animal models, Diacerein, nanomedicine and osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Osteoarthritis and Joint Biology – Basic Science Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoarthritis (OA) treatment is typically administered to control symptoms. Diacerein (DIA) reduces interleukin (IL)-1 receptor on chondrocytes and prevents structural degradation of joint tissue. Direct injection of DIA into joint is preferred to increase its bioavailability and reduce systemic side effects. We investigated whether poly(d,l–lactide-co-glycolide) (PLGA) nanoparticles (NPs) could effectively deliver DIA and inhibit the inflammatory reaction.

Methods: Monosodium iodoacetate (MIA)-induced OA rats were divided into seven groups with injection of MIA alone (group 1) and with, NPs (2), 5% DIA (3), 1% DIA/NPs (4) or 5% DIA/NPs (5), oral DIA (6), and non-treated healthy control rats (7). The mRNA expression of pro-inflammatory cytokines and derived enzymes were investigated, including interleukin (IL)-1, IL-6, tumor necrosis factor-alpha (TNF-¥á), matrix metalloproteinase (MMP)-3, MMP-13, cyclo-oxygenase (COX)-2, and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-5. Macroscopic, radiographic, and histologic evaluations of the joints were done at 8 weeks of DIA treatment.

Results: In group 5, the mRNA expression of inflammatory cytokines and derived enzymes decreased gradually and significantly compared with groups 1–4. Group 3 levels of mRNA expression were decreased at 5 weeks similar to that of group 5, but increased at 9 weeks. Group 6 displayed the lowest mRNA levels of inflammatory cytokines and derived enzymes, except for IL-6, which was lowest in group 5. Macroscopic erosions were fewest in group 5, followed in order by groups 6, 4, and 3. Micro-computed tomography revealed only slight irregularity of the joint surface and minimal erosion of articular cartilage in group 5 and 6.

Conclusion: Intra-articular injection of DIA/NPs inhibited the inflammatory reaction and progression in OA, with histologically less cartilage damage detected than induced by oral DIA. The 5% DIA/NPs dose produced significant reductions of the serum IL-6 levels compared with oral administration, and is a candidate treatment for the inhibition of inflammation and protection of the cartilage in OA.


Disclosure: J. H. Jung, None; S. J. Choi, None; G. G. Song, None; S. E. Kim, None; H. J. Kim, None.

To cite this abstract in AMA style:

Jung JH, Choi SJ, Song GG, Kim SE, Kim HJ. Comparison of Oral Administration of Diacerein, Intra-Articular Injection of Diacerein Solution, and Intra-Articular Injection of Diacerein-Loaded Nanoparticle in Osteoarthritis Rat Model [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/comparison-of-oral-administration-of-diacerein-intra-articular-injection-of-diacerein-solution-and-intra-articular-injection-of-diacerein-loaded-nanoparticle-in-osteoarthritis-rat-model/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-oral-administration-of-diacerein-intra-articular-injection-of-diacerein-solution-and-intra-articular-injection-of-diacerein-loaded-nanoparticle-in-osteoarthritis-rat-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology